Physician profile
Thomas Barbaro
NPI 1689661001
$1,090.75
in general payments reported to CMS, 2019-2025
12 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $255 · 2021: $139 · 2022: $43.69 · 2023: $84.11 · 2024: $124 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $281.79 | 2024-2025 | |
| Organogenesis INC. | $224.64 | 2019-2024 | Puraply |
| Osteomed LLC | $149.29 | 2020 | |
| Smith+Nephew, INC. | $110.72 | 2019-2022 | |
| Stryker Corporation | $70.29 | 2024-2025 | Flexband, Allowrap |
| Zimmer Biomet Holdings, INC. | $54.15 | 2021 | |
| Paragon 28, INC. | $51.35 | 2021-2024 | Precision Mis Bunion |
| Misonix INC | $49.81 | 2020 | |
| Polynovo North America LLC | $32.96 | 2025 | Novosorb Btm |
| Abbvie INC. | $25.64 | 2021 | |
| Horizon Therapeutics Plc | $21.40 | 2022 | |
| Fidia Pharma USA INC. | $18.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Barbaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.